Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience

---

Atıf İçin Kopyala

Akman T., ÖZTOP İ., ÜNEK İ. T., Koca D., Unal O. U., Salman T., ...Daha Fazla

CHEMOTHERAPY, cilt.60, sa.4, ss.228-238, 2014 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 60 Sayı: 4
• Basım Tarihi: 2014
• Doi Numarası: 10.1159/000371838
• Dergi Adı: CHEMOTHERAPY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.228-238
• Anahtar Kelimeler: Interferon, Treatment, Melanoma, Prognostic factors, Survival, Clinicopathological features, AMERICAN JOINT COMMITTEE, COOPERATIVE-ONCOLOGY-GROUP, PRIMARY CUTANEOUS MELANOMA, POOLED ANALYSIS, STAGING SYSTEM, FOLLOW-UP, THERAPY, CANCER, TRIAL, DACARBAZINE
• Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Surgical excision constitutes an important part of the treatment of local advanced malignant melanoma. Due to the high recurrence risk, adjuvant high-dose interferon therapy is still the only therapy used in stage IIB and III high-risk melanoma patients. Methods: One hundred two high-risk malignant melanoma patients who received high-dose interferon-alpha-2b therapy were evaluated retrospectively. The clinicopathological features, survival times, and prognostic factors of the patients were determined. Results: The median disease-free and overall survival times were 25.2 and 60.8 months, respectively. Our findings revealed that male gender, advanced disease stage, lymph node involvement, lymphatic invasion, the presence of ulceration, and a high Clark level were significant negative prognostic factors. Conclusion: In light of the favorable survival results obtained in this study, high-dose interferon treatment as adjuvant therapy for high-risk melanoma is still an efficient treatment and its possible side effects can be prevented by taking the necessary precautions. (C) 2015 S. Karger AG, Basel